# Acclarent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acclarent

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.acclarent.com
- Total disclosed funding: $76M
- Latest round: Series D (Dec 3, 2008)
- Investors on record: 5

## About

Acclarent, Inc. delivers innovative medical technologies specifically designed for the Ear, Nose, and Throat (ENT) sector, enhancing patient care through minimally invasive procedures and advanced surgical navigation systems.Acclarent, Inc. specializes in creating medical devices for the ENT field. The firm was founded in 2004 in Menlo Park, US, and was acquired by Johnson & Johnson in January 2010 for USD 785 mn. The company has successfully completed a total of 6 deals since its inception.Acclarent, through its division under Integra LifeSciences, focuses on advanced medical technologies for ENT applications. Its principal products include the ACCLARENT AERA® Eustachian Tube Balloon Dilation System and the INSPIRA AIR® Balloon Dilation System, which treat Eustachian Tube Dysfunction (ETD) and nasal airway obstruction (NAO). Additionally, the TruDi® Navigation System offers real-time 3D visualization for enhanced surgical accuracy, catering to hospitals, surgery centers, and healthcare providers seeking efficient surgical solutions.Integra LifeSciences generates revenue through direct sales and partnerships with healthcare professionals. Physicians purchase the ACCLARENT AERA® and INSPIRA AIR® systems for clinical use, with pricing reflecting the specialized nature of the devices. This approach supports a consistent revenue stream from both established and new clients in the medical community.Following its recent acquisition in January 2010, Acclarent, Inc. aims to leverage its resources to design and launch new products targeting the ENT market. Specific plans include expanding into international markets in Europe and Asia by 2025, utilizing funding from the acquisition to enhance product development and market penetration strategies.

## Funding rounds

- Series D, Dec 3, 2008, $26M — Delphi Ventures, Meritech Capital Partners, New Enterprise Associates, Versant Ventures, Johnson & Johnson Innovation
- Series C, Mar 28, 2007, $35M — Delphi Ventures, Meritech Capital Partners, New Enterprise Associates, Versant Ventures
- Series A, Jan 1, 2005, $15M — New Enterprise Associates, Versant Ventures
- Seed, Jun 1, 2004 — New Enterprise Associates

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Seed, Series A, Series C, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series C, Series D
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series D